A combination of drugs has been found that could trigger a self-destruction process in lung cancer cells, new research by UK scientists suggests.
A team of researchers have discovered that the combination of two drugs, called TRAIL and a CDK9 inhibitor, could lead cancer cells to self-destruct, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
The Cancer Research UK team looked at reprogramming the lung cancer cells to initiate them to ‘self-destruct’ and their findings could lead to the development of new treatments for the disease while still leaving healthy cells in the body unharmed.
Ongoing research has been made into understanding the path that cancer cells take to stay alive and not only do researchers hope their findings could lead to new treatments to help not only lung cancer patients, but those with other types of cancer as well.
November is Lung Cancer Awareness Month and brings attention to the disease which accounts for about 27% of all cancer deaths in the U.S., more than colon, breast, and prostate cancer combined.
Lung cancer does not typically show signs and symptoms in its early stages but can include a cough that doesn’t go away, shortness of breath, chest pain, coughing up blood, losing weight and bone pain.